8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Apr 8, 2026·SEC
TuHURA Biosciences, Inc.(HURA)Earnings, Financials & Key Ratios
HURA•NASDAQ
$2.24
Price updated Jul 7, 2026
AboutTuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.Show more
- Revenue$0
- EBITDA-$32M-80.9%
- Net Income-$30M-38.6%
- EPS (Diluted)-0.63+48.1%
- ROE-169.23%+49.1%
HURA Price & Volume
TuHURA Biosciences, Inc. (HURA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Liquidity Runway Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
Key Thesis Takeaways
- TuHURA Biosciences remains a high-risk, pre-revenue entity whose financial viability is entirely contingent upon the successful execution of Phase 3 clinical trials.
- The company faces significant structural fragility, evidenced by a persistent net loss of $7.5M in 2026Q1 and a reliance on dilutive financing to offset its lack of operational revenue.
- Investors should monitor the company's ability to secure additional capital, as the current cash balance of $6.3M is insufficient to support long-term development without further equity erosion.
Verdict Logic
the company's current ratio of 1.15 and limited cash reserves of $6.3M suggest an imminent risk of highly dilutive capital raises to sustain ongoing clinical operations.
HURA Growth Metrics
TuHURA Biosciences, Inc. (HURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM96.43%
Return on Capital
10 Years-291.21%
5 Years-248.63%
3 Years-178.2%
Last Year-176.3%
HURA Recent Earnings
TuHURA Biosciences, Inc. (HURA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (30%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.13-8.3%
$0.12
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.13-1.4%
$0.12
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.14+6.7%
$0.15
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.21-50.0%
$0.14
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.13vs $0.12-8.3% | — |
| Q2 2026 | Mar 31, 2026 | $0.13vs $0.12-1.4% | — |
| Q4 2025 | Nov 14, 2025 | $0.14vs $0.15+6.7% | — |
| Q3 2025 | Aug 14, 2025 | $0.21vs $0.14-50.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for TuHURA Biosciences, Inc. (HURA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.24 | $142.65M | -3.56 | — | — | -169.23% | 0.01% | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — |
Compare HURA vs Peers
TuHURA Biosciences, Inc. (HURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HURA SEC Filings & Documents
TuHURA Biosciences, Inc. (HURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when HURA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HURA Frequently Asked Questions
TuHURA Biosciences, Inc. (HURA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is HURA profitable?
TuHURA Biosciences, Inc. (HURA) reported a net loss of $30.9M for fiscal year 2025.
Dividend & Returns
Does HURA pay dividends?
TuHURA Biosciences, Inc. (HURA) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
What is HURA's return on equity?
TuHURA Biosciences, Inc. (HURA) has a return on equity (ROE) of -169.2%. Negative ROE indicates the company is unprofitable.
What is TuHURA Biosciences, Inc.'s free cash flow?
TuHURA Biosciences, Inc. (HURA) had negative free cash flow of $27.4M in fiscal year 2025, likely due to heavy capital investments.